Description:Diabetes is often associated with increased risk of deleterious muscle mass and function or sarcopenia, thus leading to physical inactivity and metabolic disorders. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an oral antidiabetic drug that promotes urinary excretion of glucose in the renal proximal tubules. However, how SGLT2 inhibition affects the skeletal muscle function in patients with diabetes remains elusive. Here, we examined the differential effect of CANA on the oxidative soleus and glycolytic EDL muscles from genetically obese diabetic db/db mice.